Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.55 |
| ▸ | APP | P05067 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.43 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.43 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.43 |
| ▸ | TET3 | O43151 | 2/20 | 0.41 |
| ▸ | FBXL19 | Q6PCT2 | 2/20 | 0.41 |
| ▸ | CXXC5 | Q7LFL8 | 2/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.41 |
| ▸ | CXXC4 | Q9H2H0 | 2/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3910628 | 0.98 | AKR1C1 (0.53) | AKR1C1APPCYP2C19CYP3A4CYP2C9 | |
| Water SCHEMBL3910626 | 0.96 | AKR1C1 (0.52) | AKR1C1APPCYP2C19CYP3A4CYP2C9 | |
| SCHEMBL9966557 | 0.92 | AKR1C1 (0.68) | AKR1C1KMT2AMEN1TSHRHDAC1 | |
| SCHEMBL1492737 | 0.92 | AKR1C1 (0.62) | AKR1C1APPCYP2C19CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL28915897 | 0.90 | AKR1C1 (0.66) | AKR1C1KMT2AMEN1TSHRHDAC1 | |
| SCHEMBL2384832 | 0.90 | AKR1C1 (0.66) | AKR1C1KMT2AMEN1TSHRHDAC1 | |
| SCHEMBL11097640 | 0.87 | AKR1C1 (0.47) | AKR1C1APPCYP2C19CYP3A4CYP2C9 | |
| SCHEMBL3032228 | 0.87 | AKR1C1 (0.47) | AKR1C1KMT2AMEN1TSHRHDAC1 | |
| SCHEMBL29134935 | 0.87 | AKR1C1 (0.47) | AKR1C1APPCYP2C19CYP3A4CYP2C9 | |
| SCHEMBL2325209 | 0.87 | HDAC1 (0.55) | AKR1C1CYP2C19CYP2C9KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 425 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | SITRYX THERAPEUTICS LIMITED (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20260103464-A1 | CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2026-04-16 | — | — | US | disclosed |
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4081511-B3 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2026-03-04 | — | — | EP | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12435083-B2 | Cyclopropyl-(hetero)aryl-substituted ethylsulphonyl-pyridine derivatives | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-10-07 | — | — | US | disclosed |
| US-12410160-B2 | KHK inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12377083-B2 | Lysophosphatidic acid receptor antagonist and preparation method therefor | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-08-05 | — | — | US | disclosed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-6380256-B1 | FOR THERAPY OF DISEASES RESPONSIVE TO TREATMENT BY RETINOIDS | ALLERGAN SALES, INC. | 2002-04-30 | — | — | US | disclosed |
| US-6369225-B1 | ENZYME INHIBITORS | ALLERGAN SALES, INC. | 2002-04-09 | — | — | US | disclosed |
| US-6369261-B1 | CYCLOPROPYLBENZENE DERIVATIVE OF ACIDS OR ESTERS | ALLERGAN SALES, INC. | 2002-04-09 | — | — | US | disclosed |
| WO-2002026727-A2 | METHODS OF PROVIDING AND USING COMPOUNDS (RETINOIDS) HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | ALLERGAN, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| US-6359135-B1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN SALES, INC. | 2002-03-19 | — | — | US | disclosed |
| WO-2002018361-A2 | COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | ALLERGAN, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| US-6313107-B1 | ADMINISTERING TO MAMMAL TO TREAT DISEASES RESPONSIVE TO TREATMENT BY RETINOIDS | ALLERGAN SALES, INC. | 2001-11-06 | — | — | US | disclosed |
| US-6303785-B1 | SUBSTITUTED N-CYCLOPROPYLTETRAHYDROISOQUINOLINES | ALLERGAN SALES, INC. | 2001-10-16 | — | — | US | disclosed |
| US-6291677-B1 | FOR TREATING SKIN-RELATED DISEASES, INCLUDING, ACTINIC KERATOSES, ARSENIC KERATOSES, INFLAMMATORY AND NON-INFLAMMATORY ACNE, PSORIASIS, ICHTHYOSES AND KERATINIZATION AND HYPERPROLIFERATIVE DISORDERS OF SKIN | ALLERGAN SALES, INC. | 2001-09-18 | — | — | US | disclosed |
| US-6252090-B1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN SALES, INC. | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377083-B2 | Lysophosphatidic acid receptor antagonist and preparation method therefor | LPAR1, LPAR2, LPAR4 | AKR1C1 604/4885APP 2407/4885CYP2C19 2309/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | AKR1C1 289/4885APP 4578/4885CYP2C19 735/4885 |
| US-12410160-B2 | KHK inhibitors | KHK, KHDRBS1, NADK | AKR1C1 804/4885APP 4607/4885CYP2C19 622/4885 |
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | CCR1, CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | AKR1C1 238/4885APP 4848/4885CYP2C19 3664/4885 |
| US-12435083-B2 | Cyclopropyl-(hetero)aryl-substituted ethylsulphonyl-pyridine derivatives | CYCS, CYP2E1, CYP1A1 | AKR1C1 1131/4885APP 3125/4885CYP2C19 16/4885 |
| US-20260103464-A1 | CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES | CBR3, CYCS, CBR1 | AKR1C1 579/4885APP 4859/4885CYP2C19 886/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | AKR1C1 239/4885APP 4415/4885CYP2C19 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.